[HTML][HTML] The oncology biomarker discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer
AJ Ohnmacht, A Stahler, S Stintzing, DP Modest… - Nature …, 2023 - nature.com
Precision medicine has revolutionised cancer treatments; however, actionable biomarkers
remain scarce. To address this, we develop the Oncology Biomarker Discovery (OncoBird) …
remain scarce. To address this, we develop the Oncology Biomarker Discovery (OncoBird) …
[HTML][HTML] The evolving biomarker landscape for treatment selection in metastatic colorectal cancer
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
Chasing the personalized medicine dream through biomarker validation in colorectal cancer
Highlights•mCRC patients' survival outcomes pose major treatment challenge for
oncologists.•Personalized medicine is an evolving approach for cancer management …
oncologists.•Personalized medicine is an evolving approach for cancer management …
[HTML][HTML] Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
HY Luo, RH Xu - World Journal of Gastroenterology: WJG, 2014 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) is one of the most common human malignant diseases and the
second leading cause of cancer-related deaths worldwide. The treatment of advanced CRC …
second leading cause of cancer-related deaths worldwide. The treatment of advanced CRC …
Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study
RP Marques, AR Godinho, P Heudtlass… - Journal of cancer …, 2020 - Springer
Purpose Uncertainty exists regarding comparative effectiveness of cetuximab versus
bevacizumab in metastatic colorectal cancer (mCRC). We conducted a retrospective head-to …
bevacizumab in metastatic colorectal cancer (mCRC). We conducted a retrospective head-to …
Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.
3513 Background: Encorafenib+ binimetinib+ cetuximab (enco/bini/cetux; triplet) and enco+
cetux (doublet) regimens improved overall survival and objective response rate vs standard …
cetux (doublet) regimens improved overall survival and objective response rate vs standard …
[HTML][HTML] Targeted therapy in metastatic colorectal cancer–an example of personalised medicine in action
V Heinemann, JY Douillard, M Ducreux… - Cancer treatment …, 2013 - Elsevier
In metastatic colorectal cancer (mCRC), an improved understanding of the underlying
pathology and molecular biology has successfully merged with advances in diagnostic …
pathology and molecular biology has successfully merged with advances in diagnostic …
[HTML][HTML] Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer
SH Lim, HJ Cho, KM Kim, HY Lim, WK Kang… - Oncology …, 2023 - ncbi.nlm.nih.gov
Background Although bevacizumab is an important treatment for metastatic colorectal
cancer (CRC), not all patients with CRC benefit from it; in unselected patient populations …
cancer (CRC), not all patients with CRC benefit from it; in unselected patient populations …
Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial
C Kohne, D Stroiakovski, C Chang-Chien… - Journal of Clinical …, 2009 - ascopubs.org
4068 Background: KRAS oncogene mutation status is predictive of efficacy of cetuximab
alone or combined with chemotherapy (CT) in mCRC. Previous data from the phase III …
alone or combined with chemotherapy (CT) in mCRC. Previous data from the phase III …
An update on treatment advances for the first-line therapy of metastatic colorectal cancer
JJ Lee, E Chu - The Cancer Journal, 2007 - journals.lww.com
The treatment of metastatic colorectal cancer (mCRC) has evolved significantly over the past
10 years. For nearly 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) was the only agent …
10 years. For nearly 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) was the only agent …